TICKERNERD
Menu
VRCAVRCAHealthcare · Biotechnology

VRCA Stock Forecast: Verrica Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$4.91
−0.81% on the day

The 7 Wall Street analysts covering Verrica Pharmaceuticals, Inc. hold a median 12-month price target of $13 — +154.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 74 of 100 as at 10 Sept 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$85.0M
Ticker Nerd rank
74 / 100
Median analyst target
$13
Analysts covering
7
Revenue$5.9M−53.8% y/y
Operating income−$11.4M
Net income−$13.2M
Free cash flow−$9.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−8.4%
1M
−5.9%
YTD
−40.9%
1Y
−0.6%
From 52W high
−46.0%
From 52W low
+49.7%
$3.28
$9.10
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

VRCA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Verrica Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 10 Sept 2026
74 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
94
Quality
79
Growth
79
Size
77
Issuance
64
Value
62
Momentum
38
Volatility
29
Revisions
28

Accruals (94): Reported profit is backed by cash, and the company is not expanding recklessly.

Revisions (28): Analysts have, on balance, been cutting their forecasts.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

VRCA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on VRCA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5.00$10.00$15.00$20.00Oct 25Jan 26Apr 26Jul 26VRCAHigh $20Median $13Low $9

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says7 analysts
6 Buy1 Hold0 Sell
Low $9Median $13High $20

The green dot is the last close — the median target sits +154.6% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
26 May 2026HC Wainwright & Co.AssumesBuy$12
18 Dec 2025Brookline CapitalUpgradeBuy—
14 May 2025NeedhamReiteratesHold—
9 Apr 2025NeedhamReiteratesHold—
8 Apr 2025HC Wainwright & Co.ReiteratesNeutral—
12 Mar 2025NeedhamReiteratesHold—
20 Dec 2024NeedhamReiteratesHold—
6 Nov 2024HC Wainwright & Co.DowngradeNeutral—
5 Nov 2024NeedhamReiteratesHold—
5 Nov 2024RBC CapitalDowngradeSector Perform—
21 Oct 2024TD CowenMaintainsBuy—
4 Oct 2024RBC CapitalMaintainsOutperform—
3 Oct 2024NeedhamDowngradeHold—
2 Oct 2024Brookline CapitalDowngradeHold—
15 Aug 2024NeedhamMaintainsBuy—
15 Aug 2024RBC CapitalMaintainsOutperform—
16 May 2024NeedhamReiteratesBuy—
14 May 2024HC Wainwright & Co.MaintainsBuy—
14 May 2024NeedhamMaintainsBuy—
10 Apr 2024NeedhamReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. VRCA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

VRCA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Verrica Pharmaceuticals, Inc. returned −0.6% against +17.5% for the S&P 500, dividends included.

VRCA vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140160180200Oct 25Jan 26Apr 26Jul 26VRCAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

VRCA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Verrica Pharmaceuticals, Inc. (VRCA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.9×

Cheaper than 87% of US stocks

Price / sales
2.8×

Cheaper than 43% of US stocks

Price / book
19.7×

Cheaper than 5% of US stocks

EV / EBITDA
−3.0×

Cheaper than 74% of US stocks

Growth & margins
Revenue growth (YoY)
−53.9%

Higher than 5% of US stocks

Earnings growth (YoY)
−53.8%

Higher than 9% of US stocks

Gross margin
85.0%

Higher than 94% of US stocks

Operating margin
−194.5%

Higher than 11% of US stocks

Net margin
−102.8%

Higher than 6% of US stocks

Returns & dividend
Return on equity
−72.3%

Higher than 17% of US stocks

Return on assets
−44.0%

Higher than 9% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Verrica Pharmaceuticals, Inc. (VRCA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Verrica Pharmaceuticals, Inc. has a market value of $85.0M and an enterprise value of $77.5M.

  • Revenue in the twelve months to 30 June 2026: $30.3M. The latest quarter shrank 53.9% year on year.

  • Net income over the same four quarters: −$31.2M, a −102.8% net margin.

  • Diluted earnings per share, trailing twelve months: $−1.67.

  • Free cash flow in the twelve months to 30 June 2026: −$13.3M.

  • Shares outstanding: 17.2M.

  • Trailing P/E: −2.9×; forward P/E: −3.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Verrica Pharmaceuticals, Inc. employs 76 people — $399K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 11 Sept 2026

Data provided by Twelve Data

Peers

VRCA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
VRCAVerrica Pharmaceuticals, Inc.$85.0M
74
FBIOFortress Biotech, Inc.$85.4M
79
MNOVMediciNova, Inc.$85.5M
96
PTHSPelthos Therapeutics, Inc.$85.9M
21
ACRVAcrivon Therapeutics, Inc.$87.3M
67
ALDXAldeyra Therapeutics, Inc.$88.1M
51
RLYBRallybio Corp.$88.4M
54

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Verrica Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest VRCA news & analysis

Verrica Pharmaceuticals to Present YCANTH® and VP-315 Data at Two Upcoming Dermatology Conferences

GlobeNewsWire · 10 Sept 2026positive

Verrica Pharmaceuticals announced it will present YCANTH and VP-315 data at two upcoming dermatology conferences. A post-hoc analysis showed YCANTH achieved high rates of complete clearance in molluscum contagiosum patients regardless of disease duration.

Why it matters — Presentation of favorable clinical data at industry conferences could raise visibility of Verrica's product pipeline among dermatology stakeholders and investors.

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

GlobeNewsWire · 8 Sept 2026neutral

Verrica Pharmaceuticals announced that its President and CEO, Jayson Rieger, will present at the H.C. Wainwright 28th Annual Global Investment Conference. The company is a therapeutics firm developing and commercializing dermatological treatments, including for skin cancers.

Why it matters — A VRCA watcher would care because the company's CEO will present at a major investment conference, offering exposure to investors.

Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data Expected Q1 2027

GlobeNewsWire · 27 Aug 2026positive

Verrica Pharmaceuticals announced completion of enrollment in COVE-2, the first pivotal Phase 3 trial evaluating YCANTH for the treatment of common warts, with topline data expected in Q1 2027. The company also noted the second pivotal trial (COVE-3) has exceeded 50% of its enrollment target, with topline data expected in mid-2027.

Why it matters — VRCA watchers would care because completion of enrollment in the first pivotal Phase 3 trial moves the common warts program closer to potential regulatory milestones, with topline data anticipated in 2027.

Verrica Pharmaceuticals Q2 Earnings Call Highlights

MarketBeat · 7 Aug 2026positive

Verrica Pharmaceuticals reported second-quarter revenue growth for its YCANTH treatment, progress in pivotal studies for common warts, and a new credit facility that management says could extend its cash runway into 2028.

Why it matters — The update touches on all three key drivers for VRCA — revenue growth of its marketed product, pipeline advancement, and improved financial runway — making it a comprehensive check-in for shareholders.

Verrica Pharmaceuticals Inc. (VRCA) Q2 2026 Earnings Call Transcript

Seeking Alpha · 7 Aug 2026neutral

Seeking Alpha published the Q2 2026 earnings call transcript for Verrica Pharmaceuticals Inc. (VRCA). The transcript covers the company's quarterly earnings discussion presented on the call.

Why it matters — A VRCA watcher would care because the earnings call transcript provides management's own account of the company's quarterly results and outlook.

FAQ

Frequently asked questions about VRCA stock

What is the VRCA stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Verrica Pharmaceuticals, Inc. have a median 12-month price target of $13, with estimates ranging from $9 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is VRCA stock a buy right now?

Of the 7 analysts covering Verrica Pharmaceuticals, Inc., 6 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Verrica Pharmaceuticals, Inc. 74 out of 100 across roughly 4,600 US stocks as at 10 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank VRCA?

As at 10 Sept 2026, Verrica Pharmaceuticals, Inc. ranks 74 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (94 of 100).

Will VRCA stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +154.6% from the last close, and Ticker Nerd's factor model ranks Verrica Pharmaceuticals, Inc. 74 out of 100 as at 10 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the VRCA stock forecast for 2030?

No analyst covering Verrica Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VRCA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $9 to $20 over the next 12 months.

How has VRCA stock performed over the past year?

Verrica Pharmaceuticals, Inc. returned -0.6% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Verrica Pharmaceuticals, Inc. do?

Verrica Pharmaceuticals Inc. is a dermatology therapeutics company focused on developing and commercializing clinician-administered treatments for skin diseases that require medical intervention.

What is the latest news on VRCA?

The most recent item we track (GlobeNewsWire, 10 Sept 2026): "Verrica Pharmaceuticals to Present YCANTH® and VP-315 Data at Two Upcoming Dermatology Conferences". Verrica Pharmaceuticals announced it will present YCANTH and VP-315 data at two upcoming dermatology conferences. A post-hoc analysis showed YCANTH achieved high rates of complete clearance in molluscum contagiosum patients regardless of disease duration.

Company

About Verrica Pharmaceuticals, Inc.

Verrica Pharmaceuticals Inc. is a dermatology therapeutics company focused on developing and commercializing clinician-administered treatments for skin diseases that require medical intervention. Its current portfolio centers on YCANTH, a drug-device combination containing cantharidin for the treatment of molluscum contagiosum in adults and children, and for common warts. The company is also advancing additional dermatology programs, including VP-315 for dermatologic oncology indications and other cantharidin-based candidates for wart-related conditions. Verrica Pharmaceuticals serves physicians and patients through products designed for office-based use, with an emphasis on conditions that have limited treatment options. Headquartered in West Chester, Pennsylvania, Verrica Pharmaceuticals plays a specialized role in the dermatology market by targeting both viral skin infections and select skin-related oncology applications.

CEO Dr. Jayson M. Rieger M.B.A., Ph.D. · 76 employees · United States · https://www.verrica.com